Biotech Vertex, known for its cystic fibrosis therapies, is set to report earnings on Feb. 12 ...
Sionna Therapeutics (NASDAQ:SION) used its presentation at the Guggenheim Emerging Outlook Biotech Summit 2026 to outline its strategy to develop next-generation cystic fibrosis (CF) therapies ...
VRTX is set to report Q4 results amid strong Trikafta demand. Alyftrek launches are gaining traction while investors are ...
BUFFALO, N.Y. — Nicole Ellis completed her first 5k run in 2020, something that just a short time ago would've seemed almost impossible. "I am currently healthier than I have been in the last ten ...
Zacks Investment Research on MSN
VRTX's Q4 earnings miss mark, revenues beat on higher product sales
Vertex Pharmaceuticals VRTX reported adjusted earnings of $5.03 per share for the fourth quarter of 2025, missing the Zacks Consensus Estimate of $5.07. However, earnings rose around 26.4% year over ...
The cost of a popular Vertex Pharmaceuticals therapy could be contributing to cystic fibrosis (CF) treatment disparities around the world, researchers argued in a recent paper. Just 12% of some ...
OMAHA, Nebraska (WPVI) -- A newly-approved drug is bringing hope to many people dealing with cystic fibrosis. CF slowly robs patients of their breathing, choking lungs and other organs with thick ...
No one disputes the therapeutic value of Vertex Pharmaceuticals’ triplet drug Trikafta for cystic fibrosis—not even the cost watchdogs at the Institute for Clinical and Economic Review (ICER). But ...
COLORADO (KCNC) — Some Coloradans are sounding an alarm after learning a state board is considering capping the price of a life-saving drug. They’re worried the move could cause the manufacturer to ...
- With this approval approximately 750 people living with cystic fibrosis in Australia will be newly eligible for a CFTR modulator therapy - CF affects approximately 3,500 people in Australia. It is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results